Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tests the drug adalimumab in 30 Chinese children aged 4 to 17 with severe plaque psoriasis that hasn't responded to creams or light therapy. The main goal is to see how many children achieve at least a 75% improvement in their psoriasis symptoms after 16 weeks of treat…

This study tests a new oral drug, TQB3201, for people with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The drug works by breaking down a key protein that fuels cancer growth. The trial aims to find the safest dose and see if it can…

This study tests whether a new antibiotic called polymyxin E2, given both through a vein and as a mist inhaled into the lungs, can safely cure hospital-acquired pneumonia caused by drug-resistant bacteria. About 48 adults with this serious lung infection will receive either the n…

This early-stage trial tests a new oral drug called TQB3217 in 40 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. Researchers will also look for any…

This study tests the safety of an inhaled medication called TQC3721 in 800 people with moderate to severe chronic obstructive pulmonary disease (COPD). Participants must have completed a previous related study. The main goal is to track side effects and lab abnormalities, while a…

This study looks at the safety of a drug called adalimumab in 30 Chinese children aged 6 to 17 with moderate-to-severe Crohn's disease. Researchers will track side effects over 12, 26, and 52 weeks of treatment. The goal is to understand how safe the drug is in real-world use for…

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants are randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see if T…

This study tests a new inhaled powder called TQC3927 for people with chronic obstructive pulmonary disease (COPD). The goal is to see if different doses can improve lung function and are safe over a short treatment period. About 90 adults aged 40 to 75 with COPD will take part. T…

This study tests an inhaled medication called TQC3721 in 666 adults aged 40-80 with moderate-to-severe COPD. Participants will receive either the drug or a placebo for 24 weeks to see if it improves lung function. The goal is to find a new treatment option to help control this ch…

This study tests an experimental drug, TQ05105, in 51 adults with intermediate or high-risk myelofibrosis, a serious bone marrow disease. The drug is for patients whose previous treatment (JAK inhibitors) stopped working or caused side effects. The main goal is to see if the drug…

This early-stage trial tests a new drug called TQB3142 in 66 adults with advanced tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look f…

This study tests a new medicine called TQH3906 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial will involve 198 participants and aims to see if the drug can reduce lupus symptoms better than a placebo. It is a Phase 2 study, meaning it …

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug level…